Verona Pharma (VRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from ...

Verona Pharma stock hit a record high Thursday on continued enthusiasm for its newly launched COPD treatment, Ohtuvayre.

Fintel reports that on January 10, 2025, Roth MKM initiated coverage of Verona Pharma plc - Depositary Receipt () ...

Investors and market watchers are likely to monitor Verona Pharma's progress closely, as the company advances with its promising COPD treatment and capitalizes on its robust financial standing to ...

To participate, please dial one of the following numbers and ask to join the Verona Pharma call: +1- Ohtuvayre is indicated for the maintenance treatment of COPD allowing for broad use in COPD ...

Verona Pharma plc (Nasdaq: VRNA ... product and the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities ...

Investors and market watchers are likely to monitor Verona Pharma's progress closely, as the company advances with its promising COPD treatment and capitalizes on its robust financial standing to ...

dual inhibitor of PDE3 and PDE4 in a broad COPD populationLONDON and RALEIGH, N.C., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company ...

Verona Pharma operates in a competitive COPD market, but Ohtuvayre’s differentiated mechanism of action and competitive pricing strategy position it well against established players. The product ...

Verona Pharma's Ohtuvayre, a novel COPD treatment, achieved $36 million in Q4 sales, indicating strong market interest and unmet need for new therapies. Despite aggressive pricing, Ohtuvayre's ...

Verona Pharma is off to a promising start as it launches its first product, Ohtuvayre, a maintenance treatment for chronic obstructive pulmonary disorder (COPD). In 2024, Ohtuvayre generated sales ...

Verona Pharma has blockbuster hopes for its recently approved drug for chronic obstructive pulmonary disorder (COPD), and preliminary sales figures for the drug suggest it is heading in the right ...